DDInter909 DDInter255
Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated with a daily dosage of 300 mg or more and typically occurred in the first four weeks of therapy".. The discovery of imatinib also established a new group of therapy called "targeted therapy", since treatment can be tailored specifically to the unique cancer genetics of each patient. Imatinib was approved on February 1st,2001 by the FDA and November 7th, 2001 by the EMA; however, its European approval has been withdrawn in October 2023.[A263036,L49746,L49751]
Busulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It is not a structural analog of the nitrogen mustards. It has been used in the palliative treatment of chronic myeloid leukemia (myeloid leukemia, chronic), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.
Imatinib {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Busulfan
Imatinib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Busulfan
Imatinib {u} (Compound) upregulates {v} (Gene) NR1H2
NR1H2 {u} (Gene) is upregulated by {v} (Compound) Busulfan
Imatinib {u} (Compound) binds {v} (Gene) ABL1
ABL1 {u} (Gene) is upregulated by {v} (Compound) Busulfan
Imatinib {u} (Compound) downregulates {v} (Gene) DECR1
DECR1 {u} (Gene) is downregulated by {v} (Compound) Busulfan
Imatinib {u} (Compound) causes {v} (Side Effect) Dermatitis bullous
Dermatitis bullous {u} (Side Effect) is caused by {v} (Compound) Busulfan
Imatinib {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is associated with {v} (Gene) GSTM1
GSTM1 {u} (Gene) is bound by {v} (Compound) Busulfan
Imatinib {u} (Compound) upregulates {v} (Gene) NR1H2
NR1H2 {u} (Gene) is regulated by {v} (Gene) GFOD1
GFOD1 {u} (Gene) is upregulated by {v} (Compound) Busulfan
Imatinib {u} (Compound) binds {v} (Gene) ABL1
ABL1 {u} (Gene) is associated with {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Busulfan
Imatinib {u} (Compound) downregulates {v} (Gene) DECR1
DECR1 {u} (Gene) is regulated by {v} (Gene) GSTP1
GSTP1 {u} (Gene) is bound by {v} (Compound) Busulfan
Imatinib (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Busulfan (Compound)
Imatinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Busulfan (Compound)
Imatinib (Compound) upregulates NR1H2 (Gene) and NR1H2 (Gene) is upregulated by Busulfan (Compound)
Imatinib (Compound) binds ABL1 (Gene) and ABL1 (Gene) is upregulated by Busulfan (Compound)
Imatinib (Compound) downregulates DECR1 (Gene) and DECR1 (Gene) is downregulated by Busulfan (Compound)
Imatinib (Compound) causes Dermatitis bullous (Side Effect) and Dermatitis bullous (Side Effect) is caused by Busulfan (Compound)
Imatinib (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is associated with GSTM1 (Gene) and GSTM1 (Gene) is bound by Busulfan (Compound)
Imatinib (Compound) upregulates NR1H2 (Gene) and NR1H2 (Gene) is regulated by GFOD1 (Gene) and GFOD1 (Gene) is upregulated by Busulfan (Compound)
Imatinib (Compound) binds ABL1 (Gene) and ABL1 (Gene) is associated with hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Busulfan (Compound)
Imatinib (Compound) downregulates DECR1 (Gene) and DECR1 (Gene) is regulated by GSTP1 (Gene) and GSTP1 (Gene) is bound by Busulfan (Compound)